Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery

Journal of Nanobiotechnology, Journal Year: 2021, Volume and Issue: 19(1)

Published: Nov. 20, 2021

Abstract Background Glioma is one of the deadliest human cancers. Although many therapeutic strategies for glioma have been explored, these are seldom used in clinic. The challenges facing treatment not only involve development chemotherapeutic drugs and immunotherapeutic agents, but also lack a powerful platform that could deliver two moieties to targeted sites. Herein, we developed chemoimmunotherapy delivery vehicles based on C6 cell membranes DC create hybrid membrane-coated DTX nanosuspensions (DNS-[C6&DC]m). Results demonstrated successful membrane fusion nanosuspension functionalization, DNS-[C6&DC]m be different modes anti-glioma therapy. For drug delivery, coating applied target source cancer cells via homotypic-targeting mechanism membrane. immunotherapy, biomimetic enabled an immune response professional antigen-presenting characteristic dendritic (DCm), which carry full array antigens facilitate uptake membrane-bound tumor efficient presentation downstream n. Conclusion multifunctional nano-drug system with potential treat gliomas through tumor-targeted combined thereby presenting promising approach may utilized multiple Graphical

Language: Английский

---

Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care

JCO Precision Oncology, Journal Year: 2022, Volume and Issue: 6

Published: Dec. 1, 2022

PURPOSE The combination of whole-genome and transcriptome sequencing (WGTS) is expected to transform diagnosis treatment for patients with cancer. WGTS a comprehensive precision diagnostic test that starting replace the standard care oncology molecular testing in health systems around world; however, implementation widescale adoption this best-in-class lacking. METHODS Here, we address barriers integrating cancer diagnostics selection answer questions regarding utility different types, cost-effectiveness affordability, other practical considerations implementation. RESULTS We review current studies implementing provide synopsis clinical evidence insights into reflect on regulatory, costs, reimbursement, incidental findings aspects test. CONCLUSION an appropriate many tumor types can multiple, cascade approaches currently performed. Decreasing cost, increasing number clinically relevant aberrations discovery more complex biomarkers response, should pave way laboratories practice,

Language: Английский

---

The current clinical landscape of personalized cancer vaccines

Cancer Treatment Reviews, Journal Year: 2022, Volume and Issue: 106, P. 102383 - 102383

Published: March 25, 2022

Due to the intrinsic genetic instability of tumor cells, aberrant and novel antigens can be expressed serve as potential targets for cancer immunotherapy. This feature exploited by immunotherapy, particularly with vaccination. Personalized vaccination strategy a potent approach trigger broad-based antitumor response that is both beneficial relevant individual patients. Also, designed help elicit immunological memory long-lasting control. In this review, we describe different types personalized vaccines summarize completed ongoing clinical trials in last 10 years (database from www.clinicaltrials.gov). We also discuss pros cons using animal models, i.e. syngeneic patient-derived xenografts models genetically engineered mouse tools investigating strategies. Finally, preclinical studies seek test new emerging strategies well improving existing methods.

Language: Английский

---

Dose–response correlation for CAR-T cells: a systematic review of clinical studies

Journal for ImmunoTherapy of Cancer, Journal Year: 2022, Volume and Issue: 10(12), P. e005678 - e005678

Published: Dec. 1, 2022

The potential of chimeric antigen receptor (CAR) T cells to successfully treat hematological cancers is widely recognized. Multiple CAR-T cell therapies are currently under clinical development, with most in early stage, during which dose selection a key goal. objective this review address the question dose-dependent effects on response and/or toxicity from available trial data. For that purpose, systematic literature studies published between January 2010 and May 2022 was performed PubMed Embase search evaluated for cancers. Studies English were considered. children (age <18 years), solid tumors, bispecific cocktails excluded. As result, total 74 met inclusion criteria. Thirty-nine tested multiple levels at least >1 patient each level. Thirteen observed dose-related increase disease 23 across median three levels. Optimal efficacy seen doses 50–100 million anti-CD19 >100 anti-BCMA majority studies. findings suggest, given construct, there exists threshold optimal occurs. Dose escalation may reveal increasing rates (ORRs) until reached. However, when ORR starts plateau despite dose, further unlikely result improved but likely higher incidence severity mechanistically related adverse events.

Language: Английский

---

Development of therapeutic vaccines for the treatment of diseases

Molecular Biomedicine, Journal Year: 2022, Volume and Issue: 3(1)

Published: Dec. 8, 2022

Vaccines are one of the most effective medical interventions to combat newly emerging and re-emerging diseases. Prophylactic vaccines against rabies, measles, etc., have excellent effectiveness in preventing viral infection associated However, host immune response is unable inhibit virus replication or eradicate established diseases infected people. Therapeutic vaccines, expressing specific endogenous exogenous antigens, mainly induce boost cell-mediated immunity via provoking cytotoxic T cells elicit humoral activating B produce antibodies. The ultimate aim a therapeutic vaccine reshape for eradicating disease establishing lasting memory. Therefore, been developed treatment some infectious chronic noncommunicable Various technological strategies implemented development including molecular-based (peptide/protein, DNA mRNA vaccines), vector-based (bacterial vector yeast-based vaccines) cell-based (dendritic cell genetically modified as well combinatorial approaches. This review summarizes vaccine-induced describes status multiple types diseases, such those caused by HPV, HBV, HIV, HCV, SARS-CoV-2, cancer, hypertension, Alzheimer's disease, amyotrophic lateral sclerosis, diabetes, dyslipidemia, that evaluated recent preclinical clinical studies.

Language: Английский

---